

# Joao P De Aquino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1128738/publications.pdf>

Version: 2024-02-01

25  
papers

196  
citations

1478505

6  
h-index

1125743

13  
g-index

25  
all docs

25  
docs citations

25  
times ranked

215  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Psychiatric Consequences of Cannabinoids. <i>Clinical Therapeutics</i> , 2018, 40, 1448-1456.	2.5	48
2	The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. <i>Clinical Drug Investigation</i> , 2021, 41, 425-436.	2.2	33
3	Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting. <i>Journal of Addiction Medicine</i> , 2020, 14, e271-e273.	2.6	29
4	Adverse Consequences of Co-Occurring Opioid Use Disorder and Cannabis Use Disorder Compared to Opioid Use Disorder Only. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 527-537.	2.1	14
5	Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 181, 86-92.	2.9	10
6	Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109097.	3.2	9
7	Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans. <i>Psychopharmacology</i> , 2019, 236, 3209-3219.	3.1	8
8	An Update on the Epidemiology of Major Depressive Disorder Across Cultures. , 2018, , 309-315.		7
9	Perpetual Hunger: The Neurobiological Consequences of Long-Term Opioid Use. <i>Biological Psychiatry</i> , 2020, 87, e1-e3.	1.3	6
10	Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis. <i>Psychopharmacology</i> , 2019, 236, 2635-2640.	3.1	4
11	Impact of cannabis on non-medical opioid use and symptoms of posttraumatic stress disorder: a nationwide longitudinal VA study. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 812-822.	2.1	4
12	Brain Correlates of the Alcohol Use Disorder Pharmacotherapy Response: A Systematic Review of Neuroimaging Studies. <i>Brain Sciences</i> , 2022, 12, 386.	2.3	4
13	High potency synthetic opioids: Curbing the third wave of the opioid crisis. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 106, 9-10.	6.1	3
14	<i>Letter to the Editor:</i> Cannabis as a Solution to the Opioid Crisis: Is the Cart Before the Horse Again?. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 898-900.	2.9	3
15	Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science. <i>Addiction Biology</i> , 2022, 27, e13161.	2.6	3
16	Kraepelinâ€™s Crumbling Twin Pillars: Using Biology to Reconstruct Psychiatric Nosology From the Bottom Up. <i>Biological Psychiatry</i> , 2017, 82, e71-e74.	1.3	2
17	Enhancement of Medical Student Attitudes in the Treatment of Patients with Substance Use Disorders: a Follow-up Study. <i>Academic Psychiatry</i> , 2019, 43, 350-351.	0.9	2
18	Pharmacological treatment of pain among persons with opioid addiction: A systematic review and meta-analysis with implications for drug development. <i>Addiction Biology</i> , 2020, 26, e12964.	2.6	2

#	ARTICLE	IF	CITATIONS
19	Cannabinoids and Pain: Weeding Out Undesired Effects With a Novel Approach to Analgesia. <i>Biological Psychiatry</i> , 2018, 84, e67-e69.	1.3	1
20	Case Report: Increasing the Frequency of Intramuscular Naltrexone Administration in a High Risk Patient with Opioid use Disorder. <i>Substance Abuse</i> , 2021, 42, 493-496.	2.3	1
21	Buprenorphine Microinduction: Logistical Barriers and the Need for Convergent Evidence. <i>Clinical Drug Investigation</i> , 2021, 41, 665-665.	2.2	1
22	Multimodal Correlates of Cannabis Use among U.S. Veterans with Bipolar Disorder: An Integrated Study of Clinical, Cognitive, and Functional Outcomes. <i>Journal of Dual Diagnosis</i> , 2022, 18, 81-91.	1.2	1
23	Buprenorphine Treatment of Fentanyl-Related Opioid Use Disorder. primary care companion for CNS disorders, <i>The</i> , 2022, 24, .	0.6	1
24	Cannabinoids. , 2020, , 153-167.		0
25	Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans. <i>Psychopharmacology</i> , 2022, 239, 2809-2818.	3.1	0